Your session is about to expire
← Back to Search
LY3819253 for COVID-19 (BLAZE-1 Trial)
BLAZE-1 Trial Summary
This trial will test two drugs, LY3819253 and LY3832479, to see how effective they are against the virus that causes COVID-19. The drugs will be given to participants with early symptoms of COVID-19, and samples will be taken to determine how much virus is in the body at various times. Participation could last about 12 weeks.
- COVID-19
- Coronavirus
BLAZE-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBLAZE-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 & 3 trial • 3307 Patients • NCT04427501BLAZE-1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you give me the total figure of people who have signed up for this experiment?
"That is correct, the clinical trial is still actively recruiting patients. 3360 individuals are needed for the research study which is taking place at 100 different medical facilities."
Why is LY3819253 prescribed to patients?
"LY3819253 is an effective treatment for covid-19 in patients that are high risk for progression to severe covid-19, weigh 40 kg or more, and have mild to moderate symptoms."
What does the research say about LY3819253 thus far?
"Presently, there are five ongoing clinical trials researching LY3819253 with three of them in Phase 3. Many of the investigations are based out of Milwaukee, Wisconsin, but there are a total of 607 locations running trials for LY3819253."
What other similar research exists for this topic?
"LY3819253 has 5 studies ongoing in 287 cities and 24 countries. The first clinical trial began in 2020 and completed its Phase 2 & 3 drug approval stage that same year. 3360 patients were involved in the trial, which was sponsored by AbCellera Biologics Inc. Since 2020, a total of 18268 clinical trials have been completed."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger